Want to see IN:CONCORDBIO full AI Analyst Report?
CONCORDBIO Stock Chart & Stats
₹1248.65
₹7.90(0.63%)
At close: 4:00 PM EDT
₹1248.65
₹7.90(0.63%)
Day’s Range― - ―
52-Week Range₹987.05 - ₹1,674.85
Previous CloseN/A
Volume79.36K
Average Volume (3M)86.96K
Market Cap
₹165.37B
Enterprise Value₹101.96K
Total Cash (Recent Filing)₹4.32B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)58.4
Beta1.10
Next Earnings
Nov 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.49%
Share Statistics
EPS (TTM)26.24
Shares Outstanding104,616,200
10 Day Avg. Volume9,445
30 Day Avg. Volume86,963
Financial Highlights & Ratios
PEG Ratio-1.36
Price to Book (P/B)5.32
Price to Sales (P/S)10.16
P/FCF Ratio61.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)32.65
Revenue Forecast (FY)₹12.94B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetMinimal debt and a very low debt-to-equity profile reduce financial risk and preserve flexibility. The steadily growing equity base and consistently positive returns on equity provide a durable foundation for funding operations, absorbing volatility, and supporting future investment.
Strong ProfitabilityHealthy gross and net margins, together with solid EBIT and EBITDA margins, indicate that Concord Biotech retains meaningful earnings power in its API business. This profitability can support reinvestment and resilience even as results normalize from unusually strong prior levels.
Positive Operating Cash FlowConsistently positive operating cash flow that generally exceeds net income supports the quality of reported earnings. Reliable internal cash generation gives the company greater capacity to fund working capital, maintain operations, and pursue growth without relying heavily on external financing.
Bears Say
Revenue ContractionThe 2026 annual revenue decline interrupts the company’s earlier expansion pattern and signals weaker recent demand or business momentum. If contraction persists, it could reduce operating leverage, limit reinvestment capacity, and make sustained earnings growth harder to achieve.
Margin And Earnings NormalizationCompression from the unusually strong 2021–2023 margin levels, combined with lower net income in 2026 versus 2025, indicates that profitability has normalized. Lower earnings conversion can constrain internally funded growth and weaken the durability of past peak returns.
Free Cash Flow VolatilityFree cash flow has been uneven, including a negative year and a decline before the 2026 rebound. Such volatility suggests that reinvestment or working-capital requirements can materially affect cash available for expansion, shareholder returns, and other capital allocation priorities.
Concord Biotech Ltd. News
CONCORDBIO FAQ
What was Concord Biotech Ltd.’s price range in the past 12 months?
Concord Biotech Ltd. lowest stock price was ₹987.05 and its highest was ₹1674.85 in the past 12 months.
What is Concord Biotech Ltd.’s market cap?
Concord Biotech Ltd.’s market cap is ₹165.37B.
When is Concord Biotech Ltd.’s upcoming earnings report date?
Concord Biotech Ltd.’s upcoming earnings report date is Nov 18, 2026 which is in 56 days.
How were Concord Biotech Ltd.’s earnings last quarter?
Concord Biotech Ltd. released its earnings results on Jul 31, 2026. The company reported ₹5.6 earnings per share for the quarter, missing the consensus estimate of ₹7.333 by -₹1.733.
Is Concord Biotech Ltd. overvalued?
According to Wall Street analysts Concord Biotech Ltd.’s price is currently Overvalued.
Does Concord Biotech Ltd. pay dividends?
Concord Biotech Ltd. pays a Annually dividend of ₹7.55 which represents an annual dividend yield of 0.49%. See more information on Concord Biotech Ltd. dividends here
What is Concord Biotech Ltd.’s EPS estimate?
Concord Biotech Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Concord Biotech Ltd. have?
Concord Biotech Ltd. has 104,616,200 shares outstanding.
What happened to Concord Biotech Ltd.’s price movement after its last earnings report?
Concord Biotech Ltd. reported an EPS of ₹5.6 in its last earnings report, missing expectations of ₹7.333. Following the earnings report the stock price went up 6.533%.
Which hedge fund is a major shareholder of Concord Biotech Ltd.?
Currently, no hedge funds are holding shares in IN:CONCORDBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Concord Biotech Ltd.
Concord Biotech Limited, a biopharma company, engages in the research and development, manufacture, market, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, voclosporin, and pimecrolimus for immunosuppressants therapeutic segment; and temsirolimus, everolimus, romidepsin, doxorubicin, mitomycin, midostaurin, and dactinomycin for oncology therapeutic segment. In addition, the company provides mupirocin, mupirocin calcium, polymyxin B sulfate, fidaxomicin, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, micafungin sodium, and nystatin for anti-fungal therapeutic segment; and lovastatin and pravastatin sodium for other applications. Further, it develops daptomycin for anti-infectives applications; and epirubicin, idarubicin, and pirarubicin for oncology therapeutic segment. Additionally, the company provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India.
Technical Analysis
Biocon Limited
―
Dishman Carbogen Amcis Ltd.
―
Panacea Biotec Limited
―
Syngene International Ltd.
―
Anthem Biosciences Limited
―